Search the Newsreel

Bronstein, Gewirtz & Grossman LLC Urges Regeneron Pharmaceuticals, Inc. Investors to Act: Class Action Filed Alleging Investor Harm

Bronstein, Gewirtz & Grossman LLC has announced a class action lawsuit against Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) on behalf of investors who purchased securities between August 1, 2023, and May 15, 2024. The lawsuit alleges that Regeneron made materially false and misleading statements and …

Regeneron Pharmaceuticals (REGN) Keeps Buybacks And Dividend In Focus As Fair Value Stays In Sight

Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St. Dividend, earnings and buybacks in focus Regeneron Pharmaceuticals (REGN) has given investors several fresh data points to consider after confirming a quarterly dividend, releasing …

Regeneron Pharmaceuticals, Inc. (REGN) Stock forecasts

This article provides an analyst report on Regeneron Pharmaceuticals, Inc. (REGN), highlighting its strong growth and pipeline progress. The company specializes in developing and commercializing treatments for various diseases, including eye disease, cardiovascular disease, cancer, and inflammation, with key marketed products like low-dose Eylea …

PensionDanmark Pensionsforsikringsaktieselskab Purchases 3,619 Shares of Regeneron Pharmaceuticals, Inc. $REGN

PensionDanmark Pensionsforsikringsaktieselskab increased its stake in Regeneron Pharmaceuticals (NASDAQ:REGN) by 17.6% in the second quarter, acquiring 3,619 additional shares. The investment firm now owns 24,190 shares of REGN, valued at approximately $15.1 million. This comes amid mixed signals for Regeneron, including strong quarterly earnings, …

Regeneron Pharmaceuticals (NASDAQ: REGN) reports $177M in institutional 13F holdings

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) has filed a Form 13F holdings report as an institutional investment manager, detailing three reportable investment positions. The aggregate value of these holdings totals $177,219,142. The report indicates no other managers are included in this filing.

Catalyst Pharmaceuticals Inc (CPRX) Gewinnprognose: Zukünftige EPS & Umsatzwachstumsprognosen

NTLA Q2 Earnings In Line, Top Line Misses on Lower Regeneron Revenues

Intellia Therapeutics (NTLA) reported a Q2 2026 loss of 80 cents per share, matching consensus, but revenues of $7.7 million missed estimates due to lower collaboration revenues from Regeneron Pharmaceuticals. Despite the revenue miss, the company's cash position improved following a public offering, and …

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Regeneron Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadlines - REGN

Pomerantz LLP has announced a class action lawsuit against Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) on behalf of investors who suffered losses. The lawsuit alleges securities fraud, stemming from two disclosures regarding the Phase III Fianlimab-Libtayo Study which led to significant drops in Regeneron's stock …

Regeneron’s biggest week in a year cuts through a negative biotech tape

REGN rose 16.3% to $762.6, ranking near the top of Healthcare and Biotechnology, while the weekly Trend Signal and activity pressure still withheld full confirmation.

REGN SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Regeneron Pharmaceuticals, Inc. Shareholders Have Opportunity to Lead Class Action Lawsuit!

Bronstein, Gewirtz & Grossman, LLC has announced a class action lawsuit against Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and some of its officers. The lawsuit alleges that Regeneron made false and misleading statements regarding its Phase III Fianlimab-Libtayo study between August 1, 2025, and May …

Regeneron Pharmaceuticals, Inc. (REGN) News, Articles, Events & Latest Updates

Alnylam Pharmaceuticals, Inc. (ALNY) stock price, news, quote and history

This article provides a comprehensive overview of Alnylam Pharmaceuticals, Inc. (ALNY), including its current stock price, recent performance metrics, and key financial data. It details the company's various therapeutic products, both commercialized and in different phases of clinical trials, focusing on its RNA interference-based …

SueWallSt Reminds Regeneron Pharmaceuticals Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of September 14, 2026 - REGN

SueWallSt is notifying institutional investors of a class action lawsuit filed against Regeneron Pharmaceuticals (NASDAQ: REGN) with a lead plaintiff deadline of September 14, 2026. The lawsuit alleges that Regeneron made materially false and misleading statements regarding its Phase III Fianlimab-Libtayo Study, leading to …

Segall Bryant & Hamill LLC Makes New $1.02 Million Investment in Regeneron Pharmaceuticals, Inc. $REGN

Segall Bryant & Hamill LLC has initiated a new investment in Regeneron Pharmaceuticals (NASDAQ:REGN), acquiring 1,311 shares valued at approximately $1.02 million. This comes as Regeneron reported strong quarterly earnings, beating analyst estimates with $14.29 EPS and revenues of $4.29 billion. Analysts maintain a …

Regeneron Pharmaceuticals (REGN) jumps 16.3% as weekly rebound broadens

The biotechnology stock’s four-week gain nearly matches the one-week move, but trend and Market Dynamics readings remain mixed.

Regeneron Pharmaceuticals, Inc. $REGN Shares Sold by MassMutual Private Wealth & Trust FSB

MassMutual Private Wealth & Trust FSB reduced its stake in Regeneron Pharmaceuticals (NASDAQ:REGN) by 12.9% in the second quarter, selling 1,424 shares and retaining 9,576 shares valued at $5.97 million. Despite institutional ownership of 83.31% and a "Moderate Buy" consensus rating with a target …

Surging Earnings Estimates Signal Upside for Regeneron (REGN) Stock

REGN Stock Drop: Regeneron Clinical Trials Lead to 9% Stock Drop and Securities Fraud Class Action for Investors

A securities fraud class action lawsuit has been filed against Regeneron Pharmaceuticals (REGN) and its executives due to significant stock drops. The lawsuit alleges that Regeneron misled investors about the success of its Phase III Fianlimab-Libtayo clinical trial, which failed to achieve statistical significance …

Regeneron Pharmaceuticals Inc (REGN) reclaims momentum with 16.3% weekly advance

The four-week return has nearly matched the latest weekly jump, but inactive trend status and negative Market Dynamics keep confirmation mixed.

Does Regeneron (REGN) Prioritize Shareholder Returns Over Earnings Quality As Profit Slips Amid Rising Sales?

Regeneron Pharmaceuticals (REGN) reported increased revenue in Q2 2026 but experienced a dip in net income and diluted EPS. Despite the softer earnings, the company affirmed its quarterly dividend, signaling a commitment to shareholder returns alongside ongoing investments in R&D. Analysts hold varied views …

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of September 14, 2026 in Regeneron Pharmaceuticals, Inc. Lawsuit - REGN

The Gross Law Firm is notifying shareholders of Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) about a lead plaintiff deadline of September 14, 2026, in a class-action lawsuit. The lawsuit alleges that Regeneron made misleading statements regarding its Phase III Fianlimab-Libtayo Study, which led to significant …

REGN ALERT: Hagens Berman Alerts Regeneron Pharmaceuticals,

Hagens Berman has alerted investors of Regeneron Pharmaceuticals (REGN) about a pending securities class action lawsuit. The lawsuit stems from Regeneron's disclosures regarding a Phase 3 clinical trial for a melanoma therapy, which ultimately failed, causing a significant drop in the company's stock price …

Regeneron Pharmaceuticals, Inc. Revenue Breakdown – XETR:RGO

Regeneron Pharmaceuticals, Inc. (XETR:RGO) reported its revenue breakdown for the last fiscal year, with total revenue of €12.21 billion, primarily from its Medicines segment. This marks a decrease from the previous year's €13.72 billion. The majority of its revenue, €6.67 billion, originated from the …

Regeneron Pharma Q2 Earnings: EYLEA HD Outsold EYLEA for the First Time

REGN Investor Alert: Regeneron Pharmaceuticals, Inc. Securities Class Action Notice - Contact Levi & Korsinsky

Levi & Korsinsky, LLP has filed a class action lawsuit against Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) on behalf of investors who purchased securities between August 1, 2025, and May 15, 2026. The lawsuit alleges that Regeneron provided an overly positive view of its Phase …

7 Green Days In A Row: Regeneron Pharmaceuticals Stock Is Up 17%

Regeneron Pharmaceuticals (REGN) stock has experienced a significant surge, rising 17% over seven consecutive trading days, adding approximately $11 billion to its market value. This impressive run, which brought the company's market capitalization to $78 billion, is backed by strong fundamentals including higher-than-average revenue …

Regeneron Pharmaceuticals (REGN) Posts Strong Q2 Revenue, Is The Upside Already Priced In?

Regeneron Pharmaceuticals reported strong Q2 2026 revenue of US$4.29 billion, declared a dividend, and announced a new collaboration, leading to a significant stock rally. Despite a current valuation suggesting the stock is 8.5% undervalued with a fair value of $833.31, concerns remain regarding EYLEA …

Pacer Advisors Inc. Has $277.09 Million Position in Regeneron Pharmaceuticals, Inc. $REGN

Pacer Advisors Inc. reduced its stake in Regeneron Pharmaceuticals (NASDAQ:REGN) by 9.8% in Q1 2026, but still holds 358,633 shares valued at $277.1 million. The company reported strong Q2 earnings, exceeding expectations with $14.29 EPS and $4.29 billion in revenue, driven by Dupixent and …

3,000 Shares in Regeneron Pharmaceuticals, Inc. $REGN Bought by Militia Capital Management LLC

Militia Capital Management LLC recently acquired 3,000 shares of Regeneron Pharmaceuticals (NASDAQ:REGN) for approximately $2.32 million in the first quarter. This comes as other institutional investors have also adjusted their holdings, with Vanguard Group Inc. and Dodge & Cox increasing their stakes, while Director …

Carmignac Gestion Increases Stake in Regeneron Pharmaceuticals, Inc. $REGN

Carmignac Gestion significantly increased its stake in Regeneron Pharmaceuticals, Inc. by 133.3% in the first quarter, making it the fund's 20th largest position. Other institutional investors also modified their holdings, with hedge funds owning 83.31% of the company's stock. Insider trading activity included a …

Regeneron: Dupixent Sales Reach $6 Billion As Sanofi Repayment Unlocks Profit And Cash Flow Inflection

Regeneron reported strong Q2 2026 growth, with global Dupixent sales reaching approximately $6 billion, exceeding analyst expectations. The company also fully repaid its development balance to Sanofi, removing a significant financial drag and leading to an inflection point in profit and cash flow. This, …

How Investors May Respond To Telix Pharmaceuticals (ASX:TLX) Upgraded FY26 Guidance And Pipeline Milestones

Telix Pharmaceuticals (ASX:TLX) has reported significant positive updates including favorable Phase 1 trial data, the initiation of a Phase 3 trial, a collaboration with Regeneron, and raised its FY26 revenue guidance to over US$1 billion. These developments reinforce the company's theranostic platform strategy for …

Regeneron Pharmaceuticals, Inc. $REGN Shares Sold by Groupe la Francaise

Groupe la Francaise significantly reduced its stake in Regeneron Pharmaceuticals (REGN) by 86.4% in the first quarter, selling 2,806 shares. Despite this, Regeneron reported strong second-quarter results, exceeding analyst expectations for both EPS and revenue, driven by robust sales of Dupixent and EYLEA HD. …

July healthcare recap: Regeneron, DexCom shine as Moderna, managed-care stocks retreat

The healthcare sector outperformed the S&P 500 in July, gaining 2.45% due to strong company-specific earnings and catalysts. Regeneron, DexCom, and Baxter International were top performers, driven by solid earnings and favorable guidance. In contrast, Moderna and managed-care stocks retreated due to negative pipeline …

Regeneron (REGN) Stock Price Faces Margin Squeeze Despite 17% Revenue Growth

Regeneron Pharmaceuticals (REGN) saw its stock price jump 3% after reporting Q2 2026 earnings, including a 17% revenue increase to US$4.29 billion. Despite this growth, net income and basic EPS declined, and trailing net margin compressed from 31.4% to 27.9%, indicating a margin squeeze. …

Bank of America Corp DE Raises Stake in Regeneron Pharmaceuticals, Inc. $REGN

Bank of America Corp DE increased its stake in Regeneron Pharmaceuticals, Inc. (REGN) by 2.8% in the first quarter, bringing its total holdings to 1.19 million shares valued at approximately $919.1 million. This increase comes as Regeneron reported strong Q2 earnings, beating analyst expectations …